ATRS - Antares Pharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.8900
+0.0700 (+1.45%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close4.8200
Open4.8600
Bid4.8700 x 2200
Ask4.9400 x 3200
Day's Range4.8500 - 5.0000
52 Week Range2.5300 - 5.1300
Volume1,054,360
Avg. Volume1,597,679
Market Cap798.175M
Beta (3Y Monthly)0.93
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire

    Antares Pharma Social Media Campaign for XYOSTED® Wins MarCom Platinum Award

    The social media campaign for XYOSTED® featured a series of Facebook and Instagram ads to prime existing testosterone deficient patients for the launch of a new testosterone replacement therapy. The ads used humor and arresting imagery which focused on the challenges of other testosterone therapies such as messy application of testosterone gels and painful intramuscular injections. XYOSTED® is a once weekly, virtually painless subcutaneous injection of testosterone which can restore men’s testosterone levels into the normal range.

  • GlobeNewswire

    Antares Pharma to Present at the 31st Annual Piper Jaffray Healthcare Conference

    Antares Pharma, Inc. (ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the 31st Annual Piper Jaffray Healthcare Conference on Tuesday December 3, 2019 at 2:00 pm, Eastern Time. Antares Pharma, Inc. is a combination drug device company focused primarily on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. (AMAG), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia).

  • GlobeNewswire

    REMINDER: Antares Pharma Enters Into a Global Development Agreement With Idorsia Pharmaceuticals Ltd.

    Selatogrel, a new chemical entity (NCE), is being developed for the treatment of a suspected acute myocardial infarction (AMI) in adult patients with a history of AMI. Idorsia’s Phase 2 clinical data demonstrated that subcutaneous administration of selatogrel resulted in a potent and rapid platelet inhibition effect in patients with a history of coronary artery disease and AMI.

  • GlobeNewswire

    Antares Pharma Enters Into a Global Development Agreement With Idorsia Pharmaceuticals Ltd.

    Selatogrel, a new chemical entity (NCE), is being developed for the treatment of a suspected acute myocardial infarction (AMI) in adult patients with a history of AMI. Idorsia’s Phase 2 clinical data demonstrated that subcutaneous administration of selatogrel resulted in a potent and rapid platelet inhibition effect in patients with a history of coronary artery disease and AMI.

  • GlobeNewswire

    Antares Pharma to Present at the Jefferies 2019 London Healthcare Conference

    Antares Pharma, Inc. (ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Jefferies 2019 London Healthcare Conference on Wednesday November 20, 2019, at 11:20 am (GMT) / 6:20 am (EST) in London, UK. Antares Pharma, Inc. is a combination drug device company focused primarily on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. and Pfizer Inc. (Pfizer).

  • GlobeNewswire

    Antares Pharma Reports Third Quarter 2019 Operating and Financial Results

    Record Quarterly Revenue of $34.3 Million – Earnings Per Share of $0.01 The Company Increases Full Year 2019 Revenue Guidance to a Range of $115.0 to $120.0 Million EWING,.

  • GlobeNewswire

    Antares Pharma Announces Receipt of Final Payment From Sale of Zomajet™ Needle-Free Delivery System

    Antares Pharma, Inc. (ATRS) (“Antares” or “Company”) today announced that it has received the final payment of $2.5 million from Ferring Pharmaceuticals (“Ferring”) in connection with the previously disclosed sale of Antares’ worldwide rights, including certain fixed assets, for the ZOMAJET™ needle-free auto injector device to Ferring. Antares had been the worldwide supplier of ZOMAJET™ devices to Ferring and JCR Pharmaceutical Company Ltd. “This strategic divestiture has allowed us to continue to focus on developing combination products using our auto injector and pen platforms for ourselves and our partners,” stated Robert F. Apple, President and Chief Executive Officer of the Company.

  • GlobeNewswire

    Antares Pharma to Report Third Quarter 2019 Financial and Operating Results

    Antares Pharma, Inc. (ATRS) today announced it will release its third quarter 2019 financial results and recent operating progress before the market opens on Tuesday, November 5, 2019.  Management will host a webcast and conference call at 8:30 a.m. ET (Eastern Time) on November 5, 2019 to discuss the results.

  • GlobeNewswire

    Antares Pharma Announces Two Poster Presentations at the 2019 Sexual Medicine Society Scientific Annual Meeting

    The poster entitled “Comparison of Pharmacokinetic Profiles of Testosterone Therapy Products in Relation to Diurnal Variation of Serum Testosterone Levels” will be presented by Alexander Pastuszak, MD, PhD, University of Utah School of Medicine, Salt Lake City, Utah. The goal of the study was to review the pharmacokinetic (PK) profiles of serum testosterone in different exogenous testosterone formulations and compare these PK profiles with daily variations in endogenous serum testosterone levels. A review of daily testosterone variation studies in adult men was conducted followed by literature searches and product prescribing information review of a variety of testosterone therapies.

  • GlobeNewswire

    Antares Pharma to Present at the Ladenburg Thalmann 2019 Healthcare Conference

    Antares Pharma, Inc. (ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24, 2019 at 12:00 p.m. Eastern Time. Antares Pharma, Inc. is a combination drug device company focused primarily on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. and Pfizer Inc. (Pfizer).

  • GlobeNewswire

    Antares Pharma Reports Second Quarter 2019 Operating and Financial Results

    Record Quarterly Revenue of $28.4 Million - Double Second Quarter 2018 Revenue The Company Increases Full Year 2019 Revenue Guidance to a Range of $100.0 to $110.0 Million.

  • GlobeNewswire

    Antares Pharma to Report Second Quarter 2019 Financial and Operating Results

    Antares Pharma, Inc. (ATRS) today announced it will release its second quarter 2019 financial results and recent operating progress before the market opens on Tuesday, August 6, 2019. Antares Pharma’s proprietary products include XYOSTED™ (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.

  • GlobeNewswire

    Antares Pharma Announces Amendment to Existing Loan and Security Agreement With Hercules Capital

    Antares Pharma, Inc. (ATRS) (“Antares” or “the Company”) today announced that it has entered into an amendment to its existing loan and security agreement with Hercules Capital, Inc. (HTGC), (“Hercules”), to increase the available debt capital by $25 million for a term loan of up to $50 million. At the same time Antares also provided notice of the termination of the At-The-Market (“ATM”) equity offering facility which will be effective on July 6, 2019.

  • GlobeNewswire

    Antares Pharma to Present at the Raymond James 2019 Life Sciences and MedTech Conference

    Antares Pharma, Inc. (ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Raymond James 2019 Life Sciences and MedTech Conference on Tuesday, June 18, 2019 at 10:20 a.m. Eastern Time. Antares Pharma, Inc. is a combination drug device company focused on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery auto injector technology.  The Company has a portfolio of proprietary and partnered commercial products with several product candidates in advanced stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. and Pfizer Inc. (Pfizer).  Antares Pharma’s proprietary products include XYOSTED™ (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.

  • GlobeNewswire

    Antares Pharma to Present at the Jefferies 2019 Healthcare Conference

    Antares Pharma, Inc. (ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Jefferies 2019 Healthcare Conference on Thursday, June 6, 2019 at 11:00 a.m. Eastern Time. Antares Pharma, Inc. is a combination drug device company focused on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery auto injector technology.  The Company has a portfolio of proprietary and partnered commercial products with several product candidates in advanced stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. and Pfizer Inc. (Pfizer).  Antares Pharma’s proprietary products include XYOSTED™ (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.

  • GlobeNewswire

    Antares Pharma to Present at the B. Riley FBR Institutional Investor Conference

    Antares Pharma, Inc. (ATRS) today announced that Fred M. Powell, Executive Vice President and Chief Financial Officer, will present at the B. Riley FBR Institutional Investor Conference on Thursday May 23, 2019 at 1:30 pm Pacific Daylight Time. Antares Pharma, Inc. is a combination drug device company focused on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery auto injector technology.  The Company has a portfolio of proprietary and partnered commercial products with several product candidates in advanced stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. and Pfizer Inc. (Pfizer).  Antares Pharma’s proprietary products include XYOSTED™ (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.

  • GlobeNewswire

    Antares Pharma Reports First Quarter 2019 Operating and Financial Results

    EWING, N.J., May 02, 2019 -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”) today reported operating and financial results for the first quarter ended March 31, 2019.  The.

  • GlobeNewswire

    Antares Pharma to Report First Quarter 2019 Financial and Operating Results

    Antares Pharma, Inc. (ATRS) today announced it will release its first quarter 2019 financial results and recent operating progress before the market opens on Thursday, May 2, 2019.  Management will host a webcast and conference call at 8:30 a.m. ET (Eastern Time) on May 2, 2019 to discuss the results. Interested parties may participate in the conference call by dialing 1-800-458-4121 or 1-323-794-2597 and entering access code 2251670.  We encourage interested parties to dial into the conference call at least 10 minutes prior to the scheduled start time.  A replay of the conference call will be available from 11:30 a.m. ET on Thursday, May 2, 2019, through 11:30 a.m. ET on Saturday, June 1, 2019 by dialing 1-888-203-1112 or 1-719-457-0820 and entering the access code 2251670.  An archive of the slide presentation will also be available under the “For Investors” section of the Antares Website at www.antarespharma.com.

  • GlobeNewswire

    New Research: Key Drivers of Growth for Progress Software, Antares Pharma, National Vision, NMI, Waters, and Kelly Services — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, April 01, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire

    Antares Pharma Announces Receipt of Orphan Drug Designation for the Treatment of Ectopic Pregnancy With Methotrexate

    Antares Pharma, Inc. (ATRS) today announced receipt of orphan drug designation to evaluate the use of subcutaneous methotrexate (“MTX”) for the treatment of ectopic pregnancy that meets predefined criteria for medical management.  Antares plans to initiate a development program utilizing a proprietary auto injector device with doses of methotrexate not commercially approved or available in an auto injector in order to provide potential benefits for both patients and healthcare professionals.

  • GlobeNewswire

    Antares Pharma to Present at the Cowen and Company 39th Annual Healthcare Conference

    Antares Pharma, Inc. (ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Cowen and Company 39th Annual Healthcare Conference on Wednesday March 13, 2019 at 8:40 am Eastern Time. Antares Pharma, Inc. is a combination drug device company focused on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery auto injector technology.  The Company has a portfolio of proprietary and partnered commercial products with several product candidates in advanced stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. and Pfizer Inc. (Pfizer).  Antares Pharma’s proprietary products include XYOSTED™ (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.

  • GlobeNewswire

    Antares Pharma Appoints Dr. Karen Smith to Board of Directors and Announces Retirement of Dr. Jacques Gonella

    EWING, N.J., March 04, 2019 -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment of Dr. Karen Smith to the Company’s Board of Directors, filling the seat.

  • GlobeNewswire

    Antares Pharma Reports Fourth Quarter and Full Year 2018 Operating and Financial Results

    Record Annual Revenue of $63.6 Million, a 17% Increase Over 2017 Revenue The Company Reaffirms 2019 Revenue Guidance of $95.0 to $105.0 Million EWING, N.J.,.

  • GlobeNewswire

    Antares Pharma to Present at the Raymond James & Associates 40th Annual Institutional Investors Conference

    Antares Pharma, Inc. (ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Raymond James & Associates 40th Annual Institutional Investors Conference on Tuesday March 5, 2019 at 10:25 am Eastern Time. Antares Pharma, Inc. is a drug device combination products company focused on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery auto injector technology.  The Company has a portfolio of proprietary and partnered commercial products with several product candidates in advanced stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. and Pfizer Inc. (Pfizer).  Antares Pharma’s proprietary products include XYOSTED™ (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.

  • GlobeNewswire

    Antares Pharma to Report Fourth Quarter and Full Year 2018 Financial and Operating Results

    Antares Pharma, Inc. (ATRS) today announced it will release its fourth quarter and full year 2018 financial results and recent operating progress before the market opens on Thursday, February 28, 2019.  Management will host a webcast and conference call at 8:30 a.m. ET (Eastern Time) on February 28, 2019 to discuss the results.